Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks
MT Newswires Live
Apr 15
Orthocell (ASX:OCC) said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.
The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.
The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.